Expression of K19 and K7 in dysplastic nodules and hepatocellular carcinoma

Oncology Letters

Volumn 4, Issue 2, 2012, Pages 213-220

  Bae, Jun Sang ^a   Choi, Ha Na ^a   Noh, Sang Jae ^a   Park, Byung Hyun ^a   Jang, Kyu Yun ^a   Park, Cheol Keun ^b   Moon, Woo Sung ^a  

^a Chonbuk National University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Carcinoma; Dysplastic nodule; Hepatocellular; Keratin

Indexed keywords

ALPHA FETOPROTEIN; CYTOKERATIN 19; CYTOKERATIN 7;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CELL DEDIFFERENTIATION; CELL INFILTRATION; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DYSPLASIA; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSPLASTIC NODULE; LIVER NODULE; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; TISSUE MICROARRAY; TISSUE SECTION; TUMOR VOLUME; VIRUS HEPATITIS;

EID: 84861978789     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.731     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
3. Park YN: Update on precursor and early lesions of hepatocellular carcinomas. Arch Pathol Lab Med 135: 704-715, 2011.
4. Theise ND, Curado MP, Franceschi S, Hytiroglou P, Kudo M, Park YN, Sakamoto M, Torbenson M and Wee A: Hepatocellular carcinoma. In: WHO Classification Of Tumours Of The Digestive System. Bosman FT, Carneiro F, Hruban RH and Theise ND (eds). 4th edition. IARC Press, Lyon, pp205-216, 2010.
5. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V and Roskams T: The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 49: 138-151, 2006.
6. Zhuang PY, Zhang JB, Zhu XD, Zhang W, Wu WZ, Tan YS, HouJ, Tang ZY, Qin LX and Sun HC: Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor. Cancer 112: 2740-2748, 2008.
7. Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, ChoJY, YooJE, Choi JS and Park YN: Human hepatocellular carcinomas with 'Stemness'-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 54: 1707-1717, 2011.
8. Tsuchiya K, Komuta M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Kuzuya T, Itakura J, Nakanishi H, Takahashi Y, Kurosaki M, et al: Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. Oncology 80: 278-288, 2011.
9. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, WuWZ, Shi YH, Wu B, Yang GH, Ji Y and Fan J: High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 59: 953-962, 2010.
10. Andersen JB, Loi R, Perra A, Factor VM, Ledda-ColumbanoGM, Columbano A and Thorgeirsson SS: Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology 51: 1401-1409, 2010.
11. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A (eds): AJCC Cancer Staging Manual. 7th edition. Springer, New York, 2010.
12. Choi HN, Bae JS, Jamiyandorj U, Noh SJ, Park HS, Jang KY, Chung MJ, Kang MJ, Lee DG and Moon WS: Expression and role of SIRT1 in hepatocellular carcinoma. Oncol Rep 26: 503-510, 2011.
13. Moll R, Franke WW, Schiller DL, Geiger B and Krepler R: The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31: 11-24, 1982.
14. Lai YS, Thung SN, Gerber MA, Chen ML and Schaffner F: Expression of cytokeratins in normal and diseased livers and in primary liver carcinomas. Arch Pathol Lab Med 113: 134-138, 1989.
15. Johnson DE, Herndier BG, Medeiros LJ, Warnke RA and RouseRV: The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma. Am J Surg Pathol 12: 187-197, 1988.
16. Libbrecht L, Desmet V, Van Damme B and Roskams T: The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J Hepatol 33: 76-84, 2000.
17. Van Eyken P, Sciot R, Paterson A, Callea F, Kew MC and DesmetVJ: Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 19: 562-568, 1988.
18. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, Wang HY, Tang ZY and Xia QC: From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 3: 73-81, 2004.
19. Limaye PB, Bowen WC, Orr AV, Luo J, Tseng GC and Michalopoulos GK: Mechanisms of hepatocyte growth factor-mediated and epidermal growth factor-mediated signaling in transdifferentiation of rat hepatocytes to biliary epithelium. Hepatology 47: 1702-1713, 2008.
20. Nishikawa Y, Doi Y, Watanabe H, Tokairin T, Omori Y, Su M, Yoshioka T and Enomoto K: Transdifferentiation of mature rat hepatocytes into bile duct-like cells in vitro. Am J Pathol 166: 1077-1088, 2005.
21. Yoneda N, Sato Y, Kitao A, Ikeda H, Sawada-Kitamura S, Miyakoshi M, Harada K, Sasaki M, Matsui O and NakanumaY: Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma. Lab Invest 91: 262-272, 2011.
22. Zen C, Zen Y, Mitry RR, Corbeil D, Karbanová J, O'Grady J, Karani J, Kane P, Heaton N, Portmann BC and Quaglia A: Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl 17: 943-954, 2011.
23. Ravaioli M, Grazi GL, Ercolani G, Fiorentino M, Cescon M, Golfieri R, Trevisani F, Grigioni WF, Bolondi L and Pinna AD: Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 78: 1780-1786, 2004.
24. Nishihara Y, Aishima S, Kuroda Y, Iguchi T, TaguchiK, AsayamaY, Taketomi A, Kinukawa N, Honda H and TsuneyoshiM: Biliary phenotype of hepatocellular carcinoma after preoperative transcatheter arterial chemoembolization. J Gastroenterol Hepatol 23: 1860-1868, 2008.
25. Shackleton M, Quintana E, Fearon ER and Morrison SJ: Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138: 822-829, 2009.
26. Bomken S, Fiser K, Heidenreich O and Vormoor J: Understanding the cancer stem cell. Br J Cancer 103: 439-445, 2010.
27. Aishima S, Nishihara Y, Kuroda Y, Taguchi K, Iguchi T, TaketomiA, Maehara Y and Tsuneyoshi M: Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation: subdivision and comparison with ordinary hepatocellular carcinoma. Am J Surg Pathol 31: 783-91, 2007.
28. Lu XY, Xi T, Lau WY, Dong H, Zhu Z, Shen F, Wu MC and Cong WM: Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior. Ann Surg Oncol 18: 2210-2217, 2011.
29. Yuan RH, Jeng YM, Hu RH, Lai PL, Lee PH, Cheng CC and HsuHC: Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma. J Gastrointest Surg 15: 321-329, 2011.
30. Simon R and Sauter G: Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol 30: 1365-1372, 2002.
31. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K and Hirohashi K: Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 94: 851-857, 2003.